Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence

Trial Profile

Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 May 2016

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms PREVENT
  • Sponsors Janssen Biotech
  • Most Recent Events

    • 03 May 2016 This trial is completed in Germany, Austria, Belgium, Hungary, Czech Republic (end date:12/12/2014) and Italy as per European Clinical Trials Database record.
    • 02 Mar 2016 Primary endpoint has not been met. (Percentage of Participants With Clinical Recurrence (CR) of Crohns Disease (CD) Prior to or at Week 76), as per results published in the Gastroenterology.
    • 02 Mar 2016 Results published in the Gastroenterology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top